With exposure to paclitaxel, MCF-7/PR cells in sh-NSD1-treated group displayed reduced viability compared with that of sh-NC-treated group, indicating that NSD1 silencing increased the sensitivity to paclitaxel of paclitaxel-resistant BC cells. The gene discussed is NSD1; the disease is breast cancer.